<h1>LRRK2 Longitudinal Study</h1>
<p>The LRRK2 Longitudinal Study brings together three collaborative sites — Columbia University and Beth Israel Medical Centers in New York and the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel — collecting data and samples from participants over four years. These sites contributed clinical data from baseline to the LRRK2 Cross-sectional Study and began collecting biospecimens at follow-up visits. Baseline enrollment is completed, and longitudinal follow-up of subjects is slated to end in September 2016. Clinical data and whole blood, plasma, serum, RNA and urine samples are collected from LRRK2-positive PD patients, unaffected LRRK2 carriers, idiopathic PD patients, and control subjects over three visits.</p>
<h3>Accessing Data and Samples</h3>
<p>MJFF will make clinical data and biospecimens from the LRRK2 Longitudinal Study available to qualified researchers soon. Email <a href="mailto:resources@michaeljfox.org" class="orange">resources@michaeljfox.org</a> to be notified when the data and samples are available.</p>
<h3>Available Resources</h3>
<p>All follow-up visits take place 12-18 months after the previous visit. Please note that the number of available samples will be updated on a quarterly basis.</p>
<div>
<table style="font-size: .9em; margin-bottom: 20px;" class="studyDesignTable">
<tbody>
<tr>
<td></td>
<td colspan="4"><strong>Visit 1</strong></td>
<td colspan="4"><strong>Visit 2</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Idiopathic PD</strong></td>
<td><strong>LRRK2+ PD</strong></td>
<td><strong>LRRK2+ Carriers</strong></td>
<td><strong>Controls</strong></td>
<td><strong>Idiopathic PD</strong></td>
<td><strong>LRRK2+ PD</strong></td>
<td><strong>LRRK2+ Carriers</strong></td>
<td><strong>Controls</strong></td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>477</td>
<td>211</td>
<td>153</td>
<td>176</td>
<td>94</td>
<td>97</td>
<td>86</td>
<td>83</td>
</tr>
<tr>
<td><strong>Whole Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>57</td>
<td>61</td>
<td>40</td>
<td>52</td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>57</td>
<td>58</td>
<td>36</td>
<td>51</td>
</tr>
<tr>
<td><strong>Serum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>57</td>
<td>60</td>
<td>36</td>
<td>51</td>
</tr>
<tr>
<td><strong>RNA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>57</td>
<td>60</td>
<td>40</td>
<td>52</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53</td>
<td>56</td>
<td>37</td>
<td>52</td>
</tr>
</tbody>
</table>
</div>
<div>
<table style="font-size: .9em; margin-bottom: 20px;" class="studyDesignTable">
<tbody>
<tr>
<td></td>
<td colspan="4"><strong>Visit 3</strong></td>
<td colspan="4"><strong>Visit 4</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Idiopathic PD</strong></td>
<td><strong>LRRK2+ PD</strong></td>
<td><strong>LRRK2+ Carriers</strong></td>
<td><strong>Controls</strong></td>
<td><strong>Idiopathic PD</strong></td>
<td><strong>LRRK2+ PD</strong></td>
<td><strong>LRRK2+ Carriers</strong></td>
<td><strong>Controls</strong></td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>34</td>
<td>53</td>
<td>43</td>
<td>34</td>
<td>5</td>
<td>9</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td><strong>Whole Blood</strong></td>
<td>32</td>
<td>40</td>
<td>17</td>
<td>23</td>
<td>5</td>
<td>9</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td>32</td>
<td>40</td>
<td>13</td>
<td>22</td>
<td>5</td>
<td>9</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Serum</strong></td>
<td>32</td>
<td>40</td>
<td>12</td>
<td>22</td>
<td>5</td>
<td>9</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>RNA</strong></td>
<td>29</td>
<td>40</td>
<td>11</td>
<td>18</td>
<td>5</td>
<td>8</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td>31</td>
<td>35</td>
<td>15</td>
<td>21</td>
<td>4</td>
<td>8</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
</div>
<h3>Study Sites</h3>
<p style="margin-bottom: 10px;">If investigators are interested in accessing data or biospecimens not part of the consortium from a specific site, they may reach out to that site directly.</p>
<p><a id="lrrk2longitudinaltable"></a><a href="#geneticsTable" class="fancybox mjffButtonSm">View the Sites</a><a id="#lrrk2longitudinaltable"></a></p>
<div id="geneticsTable" style="display: none;">
<table class="studyDesignTable">
<tbody>
<tr>
<td colspan="3">
<h3>LRRK2 Longitudinal Study Sites</h3>
</td>
</tr>
<tr>
<td>New York, NY</td>
<td>Beth Israel Medical Center</td>
<td><a href="mailto:draymond@chpnet.org" target="_top">draymond@chpnet.org</a></td>
</tr>
<tr>
<td>New York, NY</td>
<td>Columbia University Medical Center</td>
<td><a href="mailto:hm28@cumc.columbia.edu" target="_top">hm28@cumc.columbia.edu</a></td>
</tr>
<tr>
<td>Tel Aviv Sourasky Medical Center in Israel</td>
<td> </td>
<td>tel: +972-3-6974704</td>
</tr>
</tbody>
</table>
</div>
